Vol 7, Supplement 4 (December 30, 2018): Translational Lung Cancer Research

Editorial

A novel biomarker protein panel for lung cancer, a promising first step

Camilo Molina-Romero, Edgar Vergara, Oscar Arrieta

PDF Pages: S304-S307 Full Text (1301) Open Access

Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer

Chen Zhao, Nobuyuki Takahashi, Arun Rajan

PDF Pages: S308-S311 Full Text (1281) Open Access

Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine

Vincenzo Di Noia, Ettore D’Argento, Sara Pilotto, Miriam Grazia Ferrara, Michele Milella, Giampaolo Tortora, Emilio Bria

PDF Pages: S312-S317 Full Text (1367) Open Access

Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?

Elizabeth J. Buss, Tony J. C. Wang

PDF Pages: S318-S320 Full Text (3220) Open Access

Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?

Brian Ko, Balazs Halmos

PDF Pages: S321-S325 Full Text (1986) Open Access

DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients’ clinical management and be a therapeutic target?

Giuseppe Lamberti, Chiara Peterle, Francesco Gelsomino

PDF Pages: S326-S328 Full Text (1001) Open Access

Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Chiara Lazzari, Vanesa Gregorc, Alessandra Bulotta, Alessia Dottore, Giuseppe Altavilla, Mariacarmela Santarpia

PDF Pages: S329-S333 Full Text (1468) Open Access

Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients

Waleed Kian, Laila C. Roisman, Nir Peled

PDF Pages: S334-S335 Full Text (1373) Open Access

Interplay between immune cells in lung cancer: beyond T lymphocytes

Juan-Manuel Hernandez-Martinez, Edgar Vergara, Edgar Montes-Servín, Oscar Arrieta

PDF Pages: S336-S340 Full Text (1037) Open Access

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

Alessandro Inno, Anna Stagno, Stefania Gori

PDF Pages: S341-S345 Full Text (2158) Open Access

Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer

Mitsuo Sato

PDF Pages: S346-S348 Full Text (1129) Open Access

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

Cesare Gridelli, Francesca Casaluce

PDF Pages: S349-S351 Full Text (1073) Open Access

Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer

Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane

PDF Pages: S352-S355 Full Text (1062) Open Access

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Jose Luis Perez-Gracia, Miguel F. Sanmamed, Ignacio Melero

PDF Pages: S356-S357 Full Text (2099) Open Access

Tumor mutational burden as predictive factor of response to immunotherapy

Maria Gonzalez-Cao, Santiago Viteri, Niki Karachaliou, Andres Aguilar, Juan Jose García-Mosquera, Rafael Rosell

PDF Pages: S358-S361 Full Text (1367) Open Access

Old myths about old patients: the case of non-small cell lung cancer

Joseph A. Pinto, Luis E. Raez

PDF Pages: S362-S363 Full Text (1114) Open Access

BRMS1 expression in resected lung adenocarcinoma

Domenico Galetta, Pamela Pizzutilo, Vito Longo

PDF Pages: S364-S366 Full Text (904) Open Access

Editorial for “Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse”

Michael Fleischhacker, Bernd Schmidt

PDF Pages: S367-S369 Full Text (1130) Open Access

Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Francesca Casaluce, Cesare Gridelli

PDF Pages: S370-S372 Full Text (1056) Open Access

Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models

Patricia A. Young, Richard J. Pietras

PDF Pages: S373-S376 Full Text (1283) Open Access

Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer

Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano

PDF Pages: S377-S380 Full Text (1654) Open Access

STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC?

Lennard Y. W. Lee, Summaya Mohammad, Thomas Starkey, Siow-Ming Lee

PDF Pages: S381-S384 Full Text (1083) Open Access

Role of immune checkpoint blockers in patients with EGFR mutation

Jeffrey Ward, Daniel Morgensztern

PDF Pages: S385-S387 Full Text (1240) Open Access

Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold

Surein Arulananda, Paul Mitchell

PDF Pages: S388-S392 Full Text (1926) Open Access

Meet the Professor

Raymond U. Osarogiagbon: lung cancer is a global challenge that needs our close cooperation!

Brad Li

PDF Pages: S393-S396 Full Text (1168) Open Access

Disclosure:

The supplement was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding.